Sage Therapeutics

Sage Therapeutics is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders. Founded in 2010 by prominent neuroscientists, the company gained significant attention for its rapid development of the first FDA-approved treatment specifically for postpartum depression. Its research strategy centers on modulating the GABA and NMDA receptor pathways, aiming to address conditions with high unmet medical need, including major depressive disorder and various neurological diseases. The company is headquartered in the biotechnology hub of Cambridge, Massachusetts.

History

The company was co-founded in 2010 by neuroscientists Steven M. Paul, Douglas Covey, and Michael R. Jackson, leveraging discoveries from Washington University in St. Louis and the National Institutes of Health. Initial venture capital funding was secured from firms including Third Rock Ventures, which helped establish its early research programs. A pivotal moment occurred in 2019 when the U.S. Food and Drug Administration approved its first drug, brexanolone, marking a historic milestone in psychiatry. Following this, the company underwent significant leadership changes, with Barry E. Greene assuming the role of CEO in 2021 after the departure of Jeffrey M. Jonas. The company's trajectory has been shaped by both its clinical successes and notable regulatory challenges, particularly surrounding subsequent drug applications.

Products and pipeline

The company's commercial portfolio includes Zuranolone, an oral medication approved for both postpartum depression and major depressive disorder, and the intravenous therapy Brexanolone specifically for postpartum depression. Its clinical pipeline features several investigational compounds targeting a range of disorders. SAGE-718, a novel NMDA receptor positive allosteric modulator, is in development for cognitive impairment associated with Huntington's disease and Alzheimer's disease. Another candidate, SAGE-324, is being studied as a potential treatment for essential tremor and other neurological conditions. The pipeline also explores next-generation GABA modulators for disorders like Parkinson's disease and epilepsy, reflecting a broad therapeutic strategy.

Research and development

The core of the company's research involves the GABA receptor system, specifically targeting neurosteroids that modulate both synaptic and extrasynaptic GABAA receptors. This approach, pioneered by founders like Steven M. Paul, aims to restore neurological balance without the side-effect profiles of traditional antidepressants like selective serotonin reuptake inhibitors. A major focus has been the role of allopregnanolone, a key neurosteroid, in mood disorders. Development efforts utilize advanced techniques in medicinal chemistry and biomarker identification to improve drug design. The research team, which includes collaborators from institutions like the University of North Carolina at Chapel Hill, also investigates the glutamate system through compounds affecting the NMDA receptor to address cognitive deficits.

Collaborations and partnerships

A major strategic collaboration was formed with Biogen in 2020 to jointly develop and commercialize zuranolone and SAGE-217 for depressive disorders, with significant upfront and milestone payments involved. The company has also engaged in research partnerships with academic centers such as the Icahn School of Medicine at Mount Sinai and Massachusetts General Hospital to advance understanding of neurosteroids. Earlier in its development, it worked with contract research organizations like QuintilesIMS (now IQVIA) to manage clinical trials. Licensing agreements have been secured for foundational intellectual property from the University of California and other research institutions. These alliances have been crucial for funding, expertise, and expanding its clinical reach.

Corporate affairs

The company is publicly traded on the NASDAQ under the ticker symbol "SAGE". Its corporate headquarters are located in Cambridge, Massachusetts, within the Kendall Square innovation district. Leadership has included notable figures from the biotechnology industry, such as Chairman Kevin Starr of Third Rock Ventures. The company has faced financial pressures following mixed regulatory outcomes, leading to restructuring efforts and workforce reductions. Its activities and drug approvals are closely monitored by analysts from firms like JP Morgan Chase and Goldman Sachs. Corporate strategy involves balancing the commercialization of approved therapies with the high-risk investment required for its extensive neurological pipeline.

Category:Biotechnology companies of the United States Category:Companies based in Cambridge, Massachusetts Category:Pharmaceutical companies established in 2010